10 Best Stocks to Buy Right Now in June 2026 – My Current Watchlist
$NVDA, $MSFT, $GOOGL, $AMZN, $TSLA, $AVGO, $AMD, $IONQ, $META, and $LLY.
Part of theAI Stocks Center
By Shayne Heffernan, Ph.D.
The market just delivered another one of those classic reset moments. After the recent tech pullback driven by hotter-than-expected jobs data, rising yields, and oil pressure from the Middle East, quality names are offering better entry points. I've watched enough of these rotations to recognize when noise creates opportunity. Here are the 10 stocks I'm focusing on right now for the remainder of 2026.
Why June 2026 Sets Up Well
The S&P 500 and Nasdaq showed some resilience in early June, with AI-related names clawing back ground after last week's selloff. AI spending continues as the dominant long-term theme, but capital is rotating toward companies with strong earnings, reasonable valuations, and real infrastructure exposure. Oil volatility and sticky inflation are keeping rate-cut expectations tempered, favoring businesses that generate solid cash flow in this environment.
This isn't the moment for blind speculation. It's time for companies with durable moats, AI tailwinds, and resilience.
My Top 10 Stocks for June 2026
$NVDA – The undisputed leader in AI infrastructure. Recent pullbacks create buying opportunities as data center demand from hyperscalers shows no signs of slowing. Long-term positioning remains exceptionally strong.
$MSFT – Enterprise AI adoption via Azure, combined with cloud strength, makes this a core holding that performs across growth and more defensive phases.
$GOOGL (Alphabet) – Search dominance plus steady advances in AI and quantum initiatives. Attractive valuation after recent weakness.
$AMZN – AWS leadership in cloud and AI services, backed by e-commerce resilience. A practical infrastructure play.
$TSLA – Tesla continues to blend AI (Full Self-Driving, Optimus robotics) with energy storage and vehicle growth. Volatility is high, but strategic positioning in AI and autonomy offers significant upside for patient investors.
$AVGO (Broadcom) – Key AI chip and networking deals position it solidly in the ongoing capex cycle.
$AMD – Gaining share as a credible alternative in AI accelerators and data center chips. Clear asymmetric upside potential.
$IONQ – Leading pure-play in trapped-ion quantum computing. Early commercial traction and hardware progress make it an interesting high-risk, high-reward addition for quantum/AI exposure.
$META – Strong advertising resilience paired with heavy AI investments across platforms. Excellent cash generation and operational efficiency.
$LLY (Eli Lilly) – Continued strength in innovative therapies, including weight-loss drugs. Provides healthcare growth exposure with defensive qualities.
Quick Comparison Table – June 2026 Outlook
Ticker | Company | Key Driver | Valuation Note | Why It Fits Now |
|---|---|---|---|---|
Nvidia | AI GPUs & data center infra | Premium | Dip-buying in core theme | |
Microsoft | Azure AI & cloud | Reasonable | Stable compounder | |
Alphabet | Search + AI/Quantum | Attractive | Post-pullback entry | |
Amazon | AWS & e-commerce | Solid | Infrastructure backbone | |
Tesla | AI autonomy, robotics & energy | Volatile | Strategic AI upside | |
Broadcom | AI networking & chips | Balanced | Capex cycle beneficiary | |
AMD | AI accelerator gains | Competitive | Challenger with momentum | |
IonQ | Quantum hardware leadership | High-risk | Quantum/AI asymmetry | |
Meta Platforms | AI-powered ads & platforms | Strong cash flow | Efficient operator | |
Eli Lilly | Pharma innovation | Growth premium | Healthcare resilience |
Market conditions change rapidly. This is for discussion purposes only — always conduct your own research.
Final Takeaways for June 2026
Use selective dips in proven AI infrastructure leaders like NVDA, MSFT, and AVGO.
Consider exposure to AI-adjacent themes including autonomy/robotics ($TSLA) and quantum computing ($IONQ).
Balance the portfolio with cash-flow generators and healthcare names that hold up in uncertain times.
Focus on companies tied to real spending cycles in AI, power infrastructure, and innovation.
The market rewards discipline in moments like these. These are the areas I'm watching most closely as we move through mid-2026.

Earnings, the Economic Calendar and Trading Strategies: September 8 to 12, 2026
A four-session week decides more than a print. Oracle reports after the close on Thursday 10 September, PPI lands that morning and CPI on Friday, with the ECB in between and the FOMC eight days out. Oracle is the last hyperscaler of the cycle and the widest value gap on the KXCO Ontology Live Analyst Outlook layer: a $457bn market value under a $638bn contracted backlog. Here is the calendar, the graph behind it, the levels and the book.

The Big Business of Longevity
Eight molecules carry an FDA label. Six carry a nonbinding committee vote. The gray market sells the second as though it were the first. A field report on the longevity pipeline, the capital behind it, and the listed names that matter.

The Hottest Biotechs of 2026
Twenty FDA approval actions so far in 2026, eight of them inside a sixteen-day window in August. A first-in-class RAS inhibitor that doubled survival in pancreatic cancer, an oral GLP-1 cleared in fifty days, a first gene therapy for GSDIa, and seven AI platforms with nine assets in humans and nothing yet approved.

The Economics of AI Tokens
A token is a private unit. Sixteen production models, one label, and a 167-fold price spread. The same support request costs 90 times more on one model than another, and losing your cache multiplies it again by up to 16.7.
Every story, signed and delivered.
Subscribe to the kxco channel and get the headline, the AI-written key takeaways, and the chain-anchor link the moment we publish. Audio versions and per-ticker subscriptions arrive in the next iteration.